GW is the global leader in developing cannabinoid-based medicines. Cannabidiol (approved by FDA as Epidiolex^® in the United States) is in development to treat certain rare and catastrophic forms of childhood-onset epilepsy that currently have few treatment options.

Healthcare Professionals: Learn more about cannabidiol (CBD) development

Clinicians & Researchers

Investors & Media

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer

RECENT NEWS

Nov 27, 2018

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress

- Epidiolex ® (cannabidiol) oral solution (CV), first FDA -approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the

Nov 26, 2018

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome

- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo - - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome - - EPIDIOLEX recently launched in the US and is now available by prescription - LONDON,

Nov 19, 2018

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Meeting Highlights Include over 20 Posters and Virtual Tour of the Epidiolex Manufacturing Process LONDON and CARLSBAD, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of

Home

RECENT NEWS